Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Researcher working on vaccine in the lab © John Cairns

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.

Today Public Health England (PHE) has submitted a pre-print of a real-world study that shows that the Oxford / AstraZeneca and Pfizer vaccines are both highly effective in reducing COVID-19 infections among older people aged 70 years and over. Both vaccines had about 60% protection against symptomatic infection in this age group.

Read the full article on the University of Oxford website

Similar stories

The lasting legacy of Norman Heatley, the unassuming penicillin pioneer who changed the course of medicine

Norman Heatley is often described as the unsung hero of the penicillin story. A recent PhD graduate with a genius for invention, he became a pivotal member of the Oxford team that developed the miracle drug in the early 1940s. A new Medium article features an interview with Norman's eldest daughter, Rose Heatley, about his work, legacy and her memories of him as a father.